Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

clarity pharmaceuticals

  • Home
  •  
  • clarity pharmaceuticals



  • Most Read
  • Latest Comments
  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • News

  • IPO Watch: The company combining cancer diagnostics and therapeutics with copper
    IPO Watch: The company combining cancer diagnostics and therapeutics with copper
    • News

  • Cannabis toothpaste is a thing, and Zelira Therapeutics are commercialising it
    Cannabis toothpaste is a thing, and Zelira Therapeutics are commercialising it
    • News

  • Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products
    • News

    Clarity Pharmaceuticals poised to enter USD $80.4 billion market with theranostics products

    Us humans are in the near constant pursuit of ever increasing efficaciousness, especially in the field of medicine. How can we harness the best possible patient outcome in the least amount of time?  Theranostics is a field of medicine combining both therapeutics and diagnostic measures to tackle the most complex medical burdens of today.  Since

    Read More
    Public
  • IPO Watch: The company combining cancer diagnostics and therapeutics with copper
    • News

    IPO Watch: The company combining cancer diagnostics and therapeutics with copper

    The complex nature of cancer means that scientists are having to get creative to improve diagnosis and treatment. Experts in the field of oncology ‘theranostics’ (combined therapeutic and diagnostic solutions), Clarity Pharmaceuticals (ASX: CU6) is due to make it’s ASX debut today. Clarity has raised $92 million at $1.40 per share. Upon listing their indicative

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.